Stem cells release an antiinflammatory microenvironment around them that influences the behavior of neighboring cells, promoting tissue regeneration and improving muscle function.


Clinical studies with stem cells have shown an improved ventricular remodeling and cardiac metabolism, which translates into a better quality of life conditions.


Stem cells secrete angiogenic factors, which promote the formation of new blood vessels from pre-existing ones in a very similar way to a sprout and splitting behavior. Conditions with poor vascularization may benefit from stem cell therapy by promoting the creation of a more developed circulatory network.


The regenerative properties of stem cells, such as increased energy efficiency and immune modulation, promote better functioning conditions. If your body is physically better, you’ll feel better too!


A typical human myocardial infarct involves the loss of approximately 1 billion cardiomyocytes and 2–3 billion other (mostly endothelial) myocardial cells, leading to a significant negative impact on the length and quality of life[1,21,22].

Although mesenchymal stem cells (MSCs) can change into different cell types, including cardiomyocytes and endothelial cells, this is not their primary mechanism of action in cardiovascular regeneration[2]. MSCs release an antiinflammatory microenvironment around them that influences the behavior of neighboring cells[3,4], such as endogenous stem cell recruitment, proliferation, and cell change and most importantly neovascularization (increase blood flow)[5-15].

MSCs secrete various molecules that induce cardioprotection by stopping cell death and increasing angiogenesis, a process that significantly increases blood flow to vital tissues [16-19,25]. Also, MSCs stimulate the proliferation and change of endogenous cardiac stem cells, thus contributing to muscle regeneration[20]. These properties have been shown by the improvement of the left ventricular remodeling[23] and cardiac metabolism[24] following MSC therapy.




Let us help you Recover your health back! Transform your life now with our Regenerative Therapies!


1. Majka M, Sulkowski M, Badyra B, Musialek P. Concise review: mesenchymal stem cells in cardiovascular regeneration: emerging research directions and clinical applications. Stem Cells Trasl Med. 2017. 6(10):1859-67.
2. Quevedo HC, Hatzistergos KE, Oskouei BM, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trinileage differenciation capacity. Proc Natl Acad Sci USA. 2009. 106:14022-7.
3. Yeo RW, Lai RC, Zhang B, et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev. 2013. 65:336-41.
4. Mokarizadeh A, Delirezh N, Morshedi A, Mosayebi G, Farshid AA, Mardani K. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol Lett. 2012. 147:47-54.
5. Hubbard RE, O’Mahony MS, Savva GM, Calver BL, Woodhouse KW. Inflammation and frailty measures in older people. J Cell Mol Med. 2009. 13(9B):3103-9.
6. Collerton J, Martin-Ruiz C, Davies K, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ study. Mech Ageing Dev. 2012. 133(6)456-66.
7. Schaap LA, Pluijm SM, Deeg DJ, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009. 64(11):1183-9.
8. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the health ABC study. J Gerontol A Biol Sci Med Sci. 2002. 57(5):M326-32.
9. Serviddio G, Romano AD, Greco A, et al. Frailty syndrome is associated with altered circulating redox balance and increased markers of oxidative stress. Int J Immunopathol Pharmacol. 2009. 22(3):819-27.
10. Tay L, Lim WS, Chan M, Ye RJ, Chong MS. The independent role of inflammation in physical frailty among older adults with mild cognitive impairment and mild-to-moderate Alzheimer’s disease. J Nutr Health Aging. 2016. 20(3):288-99.
11. Glenn JD, Whartenby KA. Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy. World J Stem Cells. 2014. 6(5):526-39.
12. Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. J Hematol Oncol. 2012. 5:19.
13. Yao X, Li H, Leng SX. Inflammation and immune system alterations in frailty. Clin Geriatr Med. 2011. 27(1):79-87.
14. Premer C, Blum A, Bellio MA, et al. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine. 2015. 2(5):467-75.
15. Aso K, Tsuruhara A, Takagaki K, et al. Adipose-derived mesenchymal stem cells restore impaired mucosal immune responses in aged mice. PLoS ONE. 2016. 11(2): e0148185.
16. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999. 284(5411):143-7.
17. Hodgkinson CP, Bareja A, Gomez JA, et al. Emerging concepts in paracrine mechanisms in regenerative cardiovascular medicine and biology. Circ Res. 2016. 118:95-107.
18. Markel TA, Wang Y, Herrmann JL, et al. VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physion Heart Circ Physiol. 2008. 295:H2308-14.
19. Mirotsou M, Zhang Z, Deb A, et al. Secreted fizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell released paracrine factor mediating myocardial survival and repair.
20. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010. 107:913-22.
21. Reinecke H, Minami E, Zhu WZ, et al. Cardiogenic differentiation and transdifferentiation of progenitor cells. Circ Res. 2008. 103:1058-71.
22. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics 2016 Update: A report from the American Heart Association. Circulation. 2016. 133:e38-60.
23. Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal tem cells with hematopoiesis supportive function and other potentials. Haematologica. 2006. 91(8):1017-26.
24. Behjati M. Suggested indications of clinical practice guideline for stem cell therapy in cardiovascular diseases: a step wise appropiate use criteria for regeneration therapy. ARYA Atheroscler. 2013. 9(5):306-10.
25. Collichia M, Jones DA, Beirne AM, et al. Umbilical cord-derived mesenchymal stromal cells in cardiovascular disease: review of preclinical and clinical data. Cytotherapy. 2019. 1-12.